• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Impact of Ketogenic Capacity on Lipid Profile in Individuals with Prediabetes or Newly Diagnosed Type 2 Diabetes.生酮能力对糖尿病前期或新诊断2型糖尿病个体血脂谱的影响。
Int J Mol Sci. 2025 Sep 3;26(17):8566. doi: 10.3390/ijms26178566.
2
Comprehensive meta-analysis of the effects of oral medroxyprogesterone acetate plus conjugated equine oestrogens on the lipid profile in women: Insights from randomized controlled trials.口服醋酸甲羟孕酮联合结合型马雌激素对女性血脂谱影响的综合荟萃分析:来自随机对照试验的见解。
Eur J Clin Invest. 2024 Aug;54(8):e14211. doi: 10.1111/eci.14211. Epub 2024 May 10.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Refining the Martin-Hopkins method for estimating low-density lipoprotein cholesterol levels: Median versus optimal TG/VLDL-C ratio.改进用于估算低密度脂蛋白胆固醇水平的Martin-Hopkins方法:中位数与最佳甘油三酯/极低密度脂蛋白胆固醇比值
PLoS One. 2025 Jul 3;20(7):e0327169. doi: 10.1371/journal.pone.0327169. eCollection 2025.
5
Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes.糖尿病护理质量改进策略:对成年糖尿病患者结局的影响。
Cochrane Database Syst Rev. 2023 May 31;5(5):CD014513. doi: 10.1002/14651858.CD014513.
6
Impact of Exercise Manual Program on Biochemical Markers in Sedentary Prediabetic Patients: A Randomized Controlled Trial.运动手册计划对久坐不动的糖尿病前期患者生化指标的影响:一项随机对照试验。
Medicina (Kaunas). 2025 Jan 22;61(2):190. doi: 10.3390/medicina61020190.
7
Alterations in lipid profiles in children with perinatally acquired HIV infection living in Ghana: A cross-sectional study.加纳围产期感染艾滋病毒儿童的血脂谱变化:一项横断面研究。
PLoS One. 2025 Jul 17;20(7):e0318314. doi: 10.1371/journal.pone.0318314. eCollection 2025.
8
Lipid Profile and Apolipoprotein B Serum Levels in the Vietnamese Population With Newly Diagnosed Elevated Low-Density Lipoprotein Cholesterol and Association With the Single-Nucleotide Variant rs676210: Cross-Sectional Study.越南新诊断为低密度脂蛋白胆固醇升高人群的血脂谱和载脂蛋白B血清水平及其与单核苷酸变体rs676210的关联:横断面研究
JMIR Cardio. 2025 Aug 7;9:e76850. doi: 10.2196/76850.
9
Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials.他伏利单抗在中国2型糖尿病合并高胆固醇血症患者中的疗效和安全性:三项3期试验汇总数据的事后分析
Cardiovasc Diabetol. 2025 Jul 3;24(1):264. doi: 10.1186/s12933-025-02816-3.
10
Beneficial effects of probiotic and synbiotic supplementation on some cardiovascular risk factors among individuals with prediabetes and type 2 diabetes mellitus: A grade-assessed systematic review, meta-analysis, and meta-regression of randomized clinical trials.益生菌和合生菌补充对糖尿病前期和 2 型糖尿病患者某些心血管危险因素的有益影响:随机临床试验的分级评估系统评价、荟萃分析和荟萃回归。
Pharmacol Res. 2022 Aug;182:106288. doi: 10.1016/j.phrs.2022.106288. Epub 2022 Jun 6.

本文引用的文献

1
Ketone Body Induction: Insights into Metabolic Disease Management.酮体诱导:对代谢性疾病管理的见解。
Biomedicines. 2025 Jun 16;13(6):1484. doi: 10.3390/biomedicines13061484.
2
Carbohydrate Restriction-Induced Elevations in LDL-Cholesterol and Atherosclerosis: The KETO Trial.碳水化合物限制导致低密度脂蛋白胆固醇升高与动脉粥样硬化:KETO试验
JACC Adv. 2024 Aug 28;3(8):101109. doi: 10.1016/j.jacadv.2024.101109. eCollection 2024 Aug.
3
2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association.《2023年韩国糖尿病管理临床实践指南:韩国糖尿病协会完整版推荐》
Diabetes Metab J. 2024 Jul;48(4):546-708. doi: 10.4093/dmj.2024.0249. Epub 2024 Jul 26.
4
Intact ketogenesis predicted reduced risk of moderate-severe metabolic-associated fatty liver disease assessed by liver transient elastography in newly diagnosed type 2 diabetes.新诊断 2 型糖尿病患者中,通过肝脏瞬时弹性成像评估,未受损酮体生成可降低中重度代谢相关脂肪性肝病风险。
Front Endocrinol (Lausanne). 2024 Jan 8;14:1306134. doi: 10.3389/fendo.2023.1306134. eCollection 2023.
5
Impaired ketogenesis is associated with metabolic-associated fatty liver disease in subjects with type 2 diabetes.在 2 型糖尿病患者中,酮生成受损与代谢相关脂肪性肝病有关。
Front Endocrinol (Lausanne). 2023 Feb 22;14:1124576. doi: 10.3389/fendo.2023.1124576. eCollection 2023.
6
Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement.韩国 2 型糖尿病患者的血脂管理:韩国糖尿病协会和韩国血脂与动脉粥样硬化学会共识声明。
Diabetes Metab J. 2023 Jan;47(1):1-9. doi: 10.4093/dmj.2022.0448. Epub 2023 Jan 20.
7
β-hydroxybutyrate as a biomarker of β-cell function in new-onset type 2 diabetes and its association with treatment response at 6 months.β-羟丁酸作为新诊断 2 型糖尿病β细胞功能的生物标志物及其与 6 个月时治疗反应的关系。
Diabetes Metab. 2023 Jul;49(4):101427. doi: 10.1016/j.diabet.2023.101427. Epub 2023 Jan 25.
8
Association between circulating oxidized OxLDL/LDL-C ratio and the severity of coronary atherosclerosis, along with other emerging biomarkers of cardiovascular disease in patients with type 2 diabetes.氧化型 OxLDL/LDL-C 比值与 2 型糖尿病患者冠状动脉粥样硬化严重程度及其他心血管疾病新兴生物标志物的相关性。
Diabetes Res Clin Pract. 2022 Sep;191:110040. doi: 10.1016/j.diabres.2022.110040. Epub 2022 Aug 17.
9
Monocyte to High-Density lipoprotein and Apolipoprotein A1 Ratios: Novel Indicators for Metabolic Syndrome in Chinese Newly Diagnosed Type 2 Diabetes.单核细胞/高密度脂蛋白和载脂蛋白 A1 比值:中国新诊断 2 型糖尿病代谢综合征的新指标。
Front Endocrinol (Lausanne). 2022 Jul 14;13:935776. doi: 10.3389/fendo.2022.935776. eCollection 2022.
10
Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations.高密度脂蛋白胆固醇水平与高危人群不良心血管结局的关系。
JAMA Cardiol. 2022 Jul 1;7(7):672-680. doi: 10.1001/jamacardio.2022.0912.

生酮能力对糖尿病前期或新诊断2型糖尿病个体血脂谱的影响。

The Impact of Ketogenic Capacity on Lipid Profile in Individuals with Prediabetes or Newly Diagnosed Type 2 Diabetes.

作者信息

Bae Jaehyun, Lee Minyoung, Lee Yong-Ho, Lee Sang-Guk, Lee Byung-Wan

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul 07441, Republic of Korea.

Division of Endocrinology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.

出版信息

Int J Mol Sci. 2025 Sep 3;26(17):8566. doi: 10.3390/ijms26178566.

DOI:10.3390/ijms26178566
PMID:40943485
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12429389/
Abstract

In individuals with non-adipogenic traits and enhanced ketogenic capacity, plasma triglyceride (TG) levels are typically low, while low-density lipoprotein cholesterol (LDL-C) levels often exceed the normal range, complicating cardiovascular risk assessment. We analyzed lipid profiles to better characterize cardiovascular risk in this population. Drug-naïve patients newly diagnosed with prediabetes or type 2 diabetes (T2D) were divided into two groups based on serum β-hydroxybutyrate levels: enhanced versus non-enhanced ketogenesis. Among those with enhanced ketogenesis, 27 individuals with high LDL-C (≥100 mg/dL) and low TG (<150 mg/dL) were selected. For comparison, 27 individuals with high TG (>150 mg/dL) from the non-enhanced group were included. The enhanced ketogenesis group demonstrated more favorable lipid characteristics, including a significantly larger average LDL particle size (26.8 ± 0.3 nm vs. 25.9 ± 0.6 nm, < 0.001), a lower proportion of small dense LDL particles, and reduced oxidized LDL to LDL-C ratio. Importantly, enhanced ketogenesis remained an independent predictor of larger LDL particle size after adjusting for potential confounders including TG. Despite the potential of selection bias intentionally induced by the predefined inclusion criteria, our findings suggest that patients with T2D or prediabetes who exhibit enhanced ketogenesis, even in the presence of elevated LDL-C levels, may have a more favorable atherogenic profile and are not necessarily at increased cardiovascular risk.

摘要

在具有非脂肪生成特征和增强的生酮能力的个体中,血浆甘油三酯(TG)水平通常较低,而低密度脂蛋白胆固醇(LDL-C)水平常常超过正常范围,这使得心血管风险评估变得复杂。我们分析了血脂谱,以更好地表征该人群的心血管风险。新诊断为糖尿病前期或2型糖尿病(T2D)且未服用药物的患者根据血清β-羟基丁酸水平分为两组:生酮增强组与非增强组。在生酮增强组中,选择了27名LDL-C水平高(≥100mg/dL)且TG水平低(<150mg/dL)的个体。为作比较,纳入了非增强组中27名TG水平高(>150mg/dL)的个体。生酮增强组表现出更有利的血脂特征,包括平均LDL颗粒大小显著更大(26.8±0.3nm对25.9±0.6nm,<0.001)、小而密LDL颗粒比例更低以及氧化LDL与LDL-C比值降低。重要的是,在调整包括TG在内的潜在混杂因素后,生酮增强仍然是LDL颗粒更大的独立预测因素。尽管预定义的纳入标准可能有意导致选择偏倚,但我们的研究结果表明,即使存在LDL-C水平升高的情况,具有增强生酮能力的T2D或糖尿病前期患者可能具有更有利的致动脉粥样硬化特征,不一定具有更高的心血管风险。